Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-10-01
DOI
10.1111/bjh.16228
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
- (2019) Laura M. McLane et al. Annual Review of Immunology
- T Cell Dysfunction in Cancer
- (2018) Daniela S. Thommen et al. CANCER CELL
- CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade
- (2018) Limo Chen et al. Cancer Discovery
- DNA Methylation Clocks in Aging: Categories, Causes, and Consequences
- (2018) Adam E. Field et al. MOLECULAR CELL
- Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
- (2018) Naval Daver et al. Cancer Discovery
- Human memory CD8 T cell effector potential is epigenetically preserved during in vivo homeostasis
- (2017) Hossam A. Abdelsamed et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia
- (2017) Niloufer Khan et al. LEUKEMIA & LYMPHOMA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- DNA Methylation in Cancer and Aging
- (2016) M. Klutstein et al. CANCER RESEARCH
- Demethylation of the PD-1 Promoter Is Imprinted during the Effector Phase of CD8 T Cell Exhaustion
- (2016) Eunseon Ahn et al. JOURNAL OF VIROLOGY
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+T-cell fate decisions following activation
- (2016) Brian H. Ladle et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection
- (2016) Matthias Hoffmann et al. PLoS Pathogens
- Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy
- (2015) Harry P. Erba LEUKEMIA RESEARCH
- Human body epigenome maps reveal noncanonical DNA methylation variation
- (2015) Matthew D. Schultz et al. NATURE
- Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
- (2015) Andreas D. Ørskov et al. Oncotarget
- Aging and epigenetic drift: a vicious cycle
- (2014) Jean-Pierre Issa JOURNAL OF CLINICAL INVESTIGATION
- Global DNA Methylation Remodeling Accompanies CD8 T Cell Effector Function
- (2013) C. D. Scharer et al. JOURNAL OF IMMUNOLOGY
- Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
- (2013) H Yang et al. LEUKEMIA
- Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy
- (2013) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells
- (2012) Hsing-Chen Tsai et al. CANCER CELL
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
- (2012) Ellen K. Ritchie et al. LEUKEMIA & LYMPHOMA
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evolution of decitabine development
- (2008) Elias Jabbour et al. CANCER
- Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine
- (2008) Carlo Stresemann et al. INTERNATIONAL JOURNAL OF CANCER
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started